[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566970":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":26,"id":52,"slug":26,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":26,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":26,"enrollmentInfo":61,"targetDuration":26,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":26,"overallStatus":36,"whyStopped":26,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Alume Biosciences, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Defining","EXPERIMENTAL","A dose defining phase for each surgical setting.",[13],"Drug: Bevonescein",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose Expansion","A dose expansion phase for each surgical setting.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Bevonescein","Bevonescein is a sterile solution that is intravenously administered",[9,15],[25],"ALM-488",null,[28],{"name":29,"role":30,"phone":31,"phoneExt":26,"email":32},"Barbara Stephens","CONTACT","6145569561","barbara.stephens@alumebiosciences.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"University of California San Diego","RECRUITING","San Diego","California","92037","United States",{"type":42,"coordinates":43},"Point",[44,45],-117.16472,32.71571,{"lat":45,"lon":44},[48],{"name":49,"role":30,"phone":26,"phoneExt":26,"email":26},"Principal Investigator",{"type":51,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100566970",false,"NCT06662097","A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery","Multicenter Open-Label Feasibility Study of Intraoperative Nerve and Ureter Visualization With Bevonescein in Patients Undergoing Minimally Invasive Abdominopelvic Surgery","Inclusion Criteria:\n\n* Must be a minimum of 18 years of age\n* Study participant is planning to proceed with surgery\n* Willing to provide informed consent\n* Sexually active patients must be willing to use an acceptable form of contraceptive while participating and 30 days after.\n* Females of childbearing potential must have a negative pregnancy test at screening and during the study.\n\nExclusion Criteria:\n\n* Patient has had prior surgery at the intended surgical site.\n* Patient has abnormal cardiac rhythm not controlled by medication.\n* Patient has moderate to severe renal impairment.\n* Patient has a history of fluorescein allergy.\n* Patient has a history of drug-related anaphylactic.\n* Presence of a concurrent disease or condition that may interfere with study participation.\n* Presence or history of any condition that, in the view of the investigator, places the patient at high risk of treatment compliance.\n* Use of any Investigational Product or investigational medial device within 30 days prior to screening.",true,"ALL","18 Years",{"count":62,"type":63},64,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery",[69,70,71],"Surgery","Nerve Injury","Imaging","2024-10-25",{"date":74,"type":75},"2024-10-28","ACTUAL",{"date":77,"type":75},"2024-10-16",{"date":79,"type":63},"2025-09",{"name":5,"class":6},1]